LOGIN
Efficacy & Safety of Selective JAK-1 Inhibitor in Treatment Of Ankylosing Spondylitis
May 2025
Efficacy & Safety of Selective JAK-1 Inhibitor in Treatment Of Ankylosing Spondylitis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis.
BMC Rheumatol . 2025 Feb 18;9(1):19.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Six studies including 1653 patients with ankylosing spondylitis were included in this systematic review and meta-analysis comparing oral upadacitinib 15 mg once daily versus placebo. Pooled outcomes of interest included ASAS20/40/PR responses, BASDAI50, ASDAS low/inactive disease, CRP, BASFI, MASES, SPARCC MRI scores, back pain scores, quality of life indices, and adverse events. Upadacitinib sign...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.